Skip to main content
SpringerLink
Log in

Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE)

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Acute bacterial endocarditis (ABE) is most commonly due to virulent pathogens, i.e., Staphylococcus aureus. S. aureus ABE may be due to methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains and, optimally, ABE should be treated with bactericidal antibiotics. Traditionally, vancomycin has long been used to treat MRSA ABE, but it has been shown that vancomycin may increase the staphylococcal the thickness, resulting in permeability-mediated resistance. We present a case of a 72-year-old male with mitral valve MRSA ABE refractory to daptomycin therapy following initial therapy with vancomycin. We were not able to diminish the intensity of the patient’s MRSA bacteremia from his mitral valve ABE, even with high-dose (12 mg/kg day) daptomycin, presumably because of permeability-mediated resistance due to antecedent vancomycin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brusch JL (2007) In: Brusch JL (ed) Infective endocarditis: management in the era of intravascular devices. Informa Healthcare USA: New York, NY

  2. Kim N, Lazar J, Cunha BA (1999) Temperatures ≥ 102°F as a prognostic feature of acute bacterial endocarditis. Infect Dis Pract 23:90–92

    Google Scholar 

  3. Baddour LM, Wilson WR, Bayer AS et al (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:394–434. doi:10.1161/CIRCULATIONAHA.105.165564

    Article  Google Scholar 

  4. Cunha BA (2006) Persistent S. aureus acute bacteremia: clinical pathway for diagnosis and treatment. Antibiotic Clin 10:39–46

    Google Scholar 

  5. Acar JF, Sabath LD (1978) Bacterial persistence in vivo: resistance or tolerance to antibiotics. Scand J Infect Dis Supp 14:86–91

    CAS  Google Scholar 

  6. Cunha BA, Ortega AM (1995) Antibiotic failure. Med Clin North Am 79:663–672

    PubMed  CAS  Google Scholar 

  7. Cui L, Ma X, Sato K et al (2003) Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14

    Article  PubMed  CAS  Google Scholar 

  8. Patel JB, Jevitt LA, Hageman J et al (2006) An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 42:1652–1653

    Article  PubMed  CAS  Google Scholar 

  9. Sakoulas G, Gold HS, Cohen RA et al (2006) Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 57:699–704

    Article  PubMed  CAS  Google Scholar 

  10. Skiest DJ (2006) Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44:655–656

    Article  PubMed  Google Scholar 

  11. Moise PA, Smyth DS, El-Fawal N et al (2008) Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Antimicrob Chemother 61:85–90

    Article  CAS  Google Scholar 

  12. Bennett JW, Murray CK, Holmes RL et al (2008) Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 60:437–440

    Article  PubMed  CAS  Google Scholar 

  13. Boucher HW, Sakoulas G (2007) Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45:601–608

    Article  PubMed  CAS  Google Scholar 

  14. Sharma M, Riederer K, Chase P et al (2008) High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 27:433–437

    Article  PubMed  CAS  Google Scholar 

  15. Sakoulas G, Rose W, Rybak MJ et al (2008) Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol 46:220–224

    Article  PubMed  CAS  Google Scholar 

  16. Rose WE, Leonard SN, Rybak MJ (2008) Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 52:3061–3067

    Article  PubMed  CAS  Google Scholar 

  17. Cunha BA (2008) Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin 24:394–420

    Google Scholar 

  18. Cunha BA, Hamid NS, Kessler H et al (2005) Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung 34:442–47

    Article  PubMed  Google Scholar 

  19. Cunha BA, Eisenstein LE, Hamid NS (2006) Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 35:207–211

    Article  PubMed  Google Scholar 

  20. Salem DN, Daudelin HD, Levine HJ et al (2001) Antithrombotic therapy in valvular heart disease. Chest 119:207–219

    Article  Google Scholar 

  21. Khatib R, Saeed S, Sharma M et al (2006) Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 25:181–185

    Article  PubMed  CAS  Google Scholar 

  22. Jones RN (2008) Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 14:3–9

    PubMed  CAS  Google Scholar 

  23. Cunha BA (2005) Clinical manifestations and antimicrobial therapy of methicillin resistant Staphylococcus aureus (MRSA). Clin Microbiol Infect 11:33–42

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Disease Division, Winthrop-University Hospital, Mineola, NY, 11501, USA

    B. A. Cunha & F. M. Pherez

  2. State University of New York School of Medicine, Stony Brook, NY, USA

    B. A. Cunha & F. M. Pherez

Authors
  1. B. A. Cunha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. M. Pherez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. A. Cunha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cunha, B.A., Pherez, F.M. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur J Clin Microbiol Infect Dis 28, 831–833 (2009). https://doi.org/10.1007/s10096-008-0692-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-008-0692-2

Keywords

Search

Navigation